Heart-homing peptide
Heart-homing peptide is a heart-targeting peptide with the sequence CRPPR that mediates cardiac endothelial targeting and accumulates in cardiac tissues. Heart-homing peptide mediates the translocation of liposomal and exosomal cargos across cardiac endothelium into interstitial tissues, enhances the accumulation of exosomes in the heart, and inhibits the GP130-STAT3/ERK1/2/AKT pathway. Heart-homing peptide accumulates at sites of ischemia/reperfusion, myocardial infarction and hypertrophy in mice. Heart-homing peptide can be used for the research of cardiovascular diseases.
For research use only. We do not sell to patients.
- CAS No.: 876460-72-9
- Formula: C25H45N11O6S
- Molecular Weight:627.76
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Exosomes displaying heart-homing peptide (4 mg/kg; i.v.; every third day; 7 doses total) preferentially accumulate in mouse hearts, significantly improve cardiac function, reduce left ventricular hypertrophy and fibrosis, and normalize hypertrophy signaling molecules in TAC-induced cardiac hypertrophy, with effects mediated via miRNA-148a-dependent suppression of the GP130-STAT3/ERK1/2/AKT pathway[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:FVB (2-month old, male, 20-25 g)[1]
-
Dosage:7 mg/kg; 20 mg/kg; 60 mg/kg
-
Administration:i.v.; single dose
-
Result:Achieved 47-fold greater fluorescence in cardiac tissue surrounding vascular lumens than non-targeted liposomes and 64-fold greater than free dye within 30 minutes of 20 mg/kg injection.
Increased tissue, endothelial, and punctate fluorescence intensities from 7 mg/kg to 20 mg/kg, with no further increase at 60 mg/kg, indicating saturation of accumulation and trans-endothelial transport.
Maintained cardiac fluorescence intensity at ~40% of the 30-minute value at 24 hours post-injection, which was significantly greater than control groups.
Detected fluorescence above non-treated controls in 37.0% of endothelial (CD31+) cells, 0.63% of cardiomyocytes (MF20+), and 5.3% of fibroblasts (Thy1.1+) at 4 hours post-injection of 60 mg/kg liposomes.
Detected fluorescence above non-treated controls in 29.1% of endothelial (CD31+) cells, 0.80% of cardiomyocytes (MF20+), and 4.0% of fibroblasts (Thy1.1+) at 12 hours post-injection of 60 mg/kg liposomes.
-
Animal Model:C57BL/6 (10-week-old male, TAC-induced pressure overload)[3]
-
Dosage:4 mg/kg
-
Administration:i.v.; every third day; 7 doses total
-
Result:Accumulated at nearly double the mean fluorescence intensity in mouse hearts 24 hours post-single intravenous administration compared to non-targeted exosomes.
Significantly ameliorated TAC-induced reductions in left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) at days 28 and 42 post-TAC, and significantly improved left ventricular end-systolic volume (LVV.s), diastolic left ventricular anterior wall thickness (LVAW.d), systolic left ventricular anterior wall thickness (LVAW.s), and left ventricular mass compared to PBS controls.
Reversed TAC-induced mean arterial blood pressure elevation from 116.70 mmHg to 92.37 mmHg.
Significantly reduced serum levels of angiotensin II (Ang II) and N-terminal pro B-type natriuretic peptide (NT-proBNP), and lung wet/dry weight ratio compared to PBS controls.
Significantly reduced TAC-induced increases in heart/body weight ratio, heart weight/tibial length ratio, and relative cardiomyocyte surface area (increased by 30% in PBS-treated TAC mice).
Significantly reduced TAC-induced upregulation of hypertrophic marker genes Acta1, Nppa, Nppb, and the Myh7/Myh6 ratio, and significantly decreased perivascular and myocardial interstitial fibrosis from 19.49% and 16.88% in PBS-treated TAC mice to 2.43% and 1.13%.
Significantly reduced TAC-induced upregulation of hypertrophy-associated proteins β-MHC, BNP, GP130, p-ERK1/2, p-AKT, and p-STAT3 in ventricular tissues.
Restored TAC-induced reduction in cardiac miRNA-148a levels to 252.30% of sham levels (vs.
66.83% in PBS-treated TAC mice).
Chemical Information
-
CAS No. 876460-72-9
-
Molecular Weight 627.76
-
Formula C25H45N11O6S
-
Sequence
Cys-Arg-Pro-Pro-Arg
-
Sequence Shortening
CRPPR
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Zhang H, et al. The cargo of CRPPR-conjugated liposomes crosses the intact murine cardiac endothelium. J Control Release. 2012;163(1):10-17. [Content Brief]
[2]. Rodríguez-Castejón J, et al. Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review. Drug Deliv Transl Res. 2024;14(10):2615-2628. [Content Brief]
[3]. Mao L, et al. Heart-targeting exosomes from human cardiosphere-derived cells improve the therapeutic effect on cardiac hypertrophy. J Nanobiotechnology. 2022;20(1):435. Published 2022 Oct 4. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz